AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...
The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...
Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
A lung cancer diagnosis can feel frightening. And when a family member is diagnosed, you might wonder about your own risk, prompting you to ask if lung cancer is hereditary. Smoking tobacco accounts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback